Elmwood Wealth Management Inc. Has $3.22 Million Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Elmwood Wealth Management Inc. reduced its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 6.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,025,740 shares of the company’s stock after selling 150,000 shares during the quarter. Caribou Biosciences makes up approximately 1.3% of Elmwood Wealth Management Inc.’s portfolio, making the stock its 26th largest position. Elmwood Wealth Management Inc. owned about 2.24% of Caribou Biosciences worth $3,221,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Green Alpha Advisors LLC boosted its holdings in shares of Caribou Biosciences by 75.4% during the fourth quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company’s stock worth $288,000 after purchasing an additional 77,840 shares during the period. Barclays PLC boosted its holdings in shares of Caribou Biosciences by 122.4% during the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after purchasing an additional 71,463 shares during the period. Geode Capital Management LLC lifted its stake in Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after acquiring an additional 124,782 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in Caribou Biosciences in the third quarter valued at approximately $28,000. Finally, PFM Health Sciences LP lifted its stake in Caribou Biosciences by 5.5% in the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after acquiring an additional 223,299 shares during the last quarter. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Friday, November 15th. Citigroup dropped their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Finally, Bank of America dropped their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Price Performance

CRBU stock traded down $0.12 on Monday, reaching $1.53. 2,362,074 shares of the company were exchanged, compared to its average volume of 1,683,964. The firm has a market capitalization of $138.09 million, a PE ratio of -0.92 and a beta of 2.34. The stock’s fifty day moving average price is $2.01 and its 200 day moving average price is $2.00. Caribou Biosciences, Inc. has a 12 month low of $1.50 and a 12 month high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. The firm had revenue of $2.02 million for the quarter, compared to analyst estimates of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. As a group, research analysts expect that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.